Apratoxin A vs Didemnin B
Head-to-head comparison of Apratoxin A (Apratoxin A) and Didemnin B (Didemnin B) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Apratoxin A | Didemnin B |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Apratoxin A | Didemnin B |
| Molecular Weight | N/A | 1112.4 Da |
| Half-Life | N/A | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | N/A in humans; nanomolar in vitro | 0.05-2 mg/m2 IV in early trials |
| Route | Intraperitoneal / Intravenous (preclinical) | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 140 | 120 |
| Research Status | Pre-clinical | Clinical |
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Research Overview
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.